An invaluable book containing a series of interdisciplinary
discussions between clinical and basic scientists. Biology
of IGF-1: Its interaction with insulin and health and malignant
states focuses on key issues such as:
* the definition of danger zones
* the development of methods for early recognition of malignant
states linked to IGF-1 and/or insulin
* possible approaches to preventative intervention
* the relevance in this field of research to the development of
novel therapeutic approaches to treating certain cancers.
Inhaltsverzeichnis
Chair’s Introduction (Leroith).
Circulating IGF-I and its role in cancer: lessons from the IGF-1
gene-deletion (LID) mouse (Yakar et al).
Physiology of the IGF system (Holly).
Molecular basis of insulin action (Zick).
IGF-1 and insulin as growth hormones (Laron).
Insulin-like growth factors and neoplasia (Pollak).
Loss of IGF2 imprinting: mechanisms and consequences
(Ohlsson).
Insulin and IGF-1 receptor trafficking and sginalling (Foti et
al).
The m TOR/S6K signalling pathway: the role of the TSC1/2 tumour
suppressor complex and the proto-oncogene Rheb (Nobukini and
Thomas).
Structural biology of insulin and IGF-1 receptors (De Meyts et
al).
Genetic blockade of the insulin-like growth factor-I receptor
for human malignancy (Adachi et al).
IGF-1 and prostate cancer (Roberts Jr.).
IGF-1 and breast cancer (Lonning and Helle).
IGFBPs and cancer (Fang et al).
The IGF receptor as anti-cancer treatment target (Macaulay).
Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary
of epidemiological evidence (Kaaks).
Final discussion.
Index of contributors.
Subject index.
Über den Autor
The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.